Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 1, Pages 96-103
Publisher
BMJ
Online
2013-10-04
DOI
10.1136/annrheumdis-2013-203660
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FRI0173 Gastrointestinal perforations with certolizumab PEGOL
- (2014) R. Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0126 Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: Primary results from doseflex, a phase IIIB study
- (2014) D.E. Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
- (2012) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Assessing the safety of biologic agents in patients with rheumatoid arthritis
- (2012) A. Rubbert-Roth RHEUMATOLOGY
- Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
- (2012) E. Choy et al. RHEUMATOLOGY
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
- (2012) M. E. Weinblatt et al. RHEUMATOLOGY
- Safety of biologic therapy in rheumatoid arthritis
- (2011) Robert S. Woodrick et al. Nature Reviews Rheumatology
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Certolizumab pegol for the treatment of Crohn’s disease
- (2011) Stefan Schreiber Therapeutic Advances in Gastroenterology
- Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
- (2010) J. D. Greenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
- (2010) D. Salmon-Ceron et al. ANNALS OF THE RHEUMATIC DISEASES
- The incidence of gastrointestinal perforations among rheumatoid arthritis patients
- (2010) Jeffrey R. Curtis et al. ARTHRITIS AND RHEUMATISM
- Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
- (2010) S. L. Westlake et al. RHEUMATOLOGY
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
- (2010) J. B. Galloway et al. RHEUMATOLOGY
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
- (2009) G R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Demyelinating events in rheumatoid arthritis after drug exposures
- (2009) S. Bernatsky et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
- (2008) J Askling et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search